Company: MDCXW
Filing Date: 2025-03-07
Form Type: 253G1
Source: 0001062993-25-004966
Chunk: 211

Company: Medicus Pharma Ltd.
Filing Date: 2025-03-07
Form: 253G1
Chunk 211
---
).

On June 25, 2024, the Board of Directors approved the acceleration of vesting for all outstanding share options to June 25, 2024, resulting in the Company recognizing the remaining expense for all share options outstanding and unvested as of that date.

Measurement of fair values

The fair value of share options granted during the period ended September 30, 2024, were estimated at the date of grant using the Black-Scholes option pricing model with the following inputs:

|                         |            2024 |
| Grant date share price  | C$1.02 - C$4.90 |
| Exercise price          | C$1.16 - C$4.84 |
| Expected dividend yield |               - |
| Risk free interest rate |   3.69% - 4.24% |
| Expected life           |         5 years |
| Expected volatility     |       96% - 97% |

Expected volatility was estimated by using the historical volatility of other companies that the Company considers comparable that have trading and volatility history. The expected option life represents the period of time that options granted are expected to be outstanding. The risk-free interest rate is based on Canadian government bonds with a remaining term equal to the expected life of the options.

7. Loss per share

Net loss per common share represents net loss attributable to common shareholders divided by the weighted average number of common shares outstanding during the period.

Diluted loss per common share is calculated by dividing the applicable net loss by the sum of the weighted average number of common shares outstanding and all additional common shares that would have been outstanding if potentially dilutive common shares had been issued during the period.

<div align='center'>F-15</div>

|                                                                        |   |       2024 |   |   | For the three months 
  ended September 30, 
                 2023 |   |   |       2024 |   |   | For the nine months 
 ended September 30, 
                2023 |   |
|:-----------------------------------------------------------------------|:--|-----------:|:--|:--|---------------------:|:--|:--|-----------:|:--|:--|--------------------:|:--|
| Net loss attributable to shareholders                                  | $ | (2,959,216 | ) | $ |           (2,963,692 | ) | $ | (8,880,935 | ) | $ |          (3,936,284 | )